Issue: May 25, 2016
April 11, 2016
1 min read
Save

Association elects 11 fellows of the AACR Academy

Issue: May 25, 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The American Association for Cancer Research elected 11 new fellows of the AACR Academy.

The AACR Academy recognizes individuals who have made significant scientific contributions and long-lasting impacts on progress against cancer. The fellows offer guidance to AACR as the organization strives to prevent and cure all cancers.

“The amazing scientific contributions made by this year’s 11 fellows have not only revolutionized cancer science, but have also provided the scientific foundation for countless other cancer professionals,” Margaret Foti, PhD, MD (hc), the association’s CEO, said in a press release. “The collective and exponential impact of their discoveries continues to be felt daily throughout the cancer field.”

This year’s fellows of the AACR Academy are: Bruce M. Alberts, PhD, of University of California, San Francisco; Clara D. Bloomfield, MD, of The Ohio State University Comprehensive Cancer Center — James Cancer Hospital and Solove Research Institute; Thomas R. Cech, PhD, of University of Colorado, Boulder; John E. Dick, PhD, of Princess Margaret Cancer Centre, Ontario Institute for Cancer Research and University of Toronto; Joe W. Gray, PhD, of Knight Cancer Institute at Oregon Health & Science University; Rudolf Jaenisch, MD, of Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology; Eric S. Lander, PhD, of Harvard Medical School; Sir David P. Lane, PhD, of Agency for Science, Technology and Research in Singapore and Ludwig Institute for Cancer Research in New York; Henry T. Lynch, MD, of Hereditary Cancer Center at Creighton University School of Medicine; Joan Massagué, PhD, of Memorial Sloan Kettering Cancer Center; and Joseph Schlessinger, PhD, of Yale School of Medicine.